About: RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations
Creator	Wasserman, Richard Greener, Benjamin Mond, James
Source	Medline; PMC
abstract	Introduction: Novel immune globulin (IG) products (RI-002, RI-001) have been designed to provide protection against respiratory syncytial virus (RSV) mediated respiratory illness while at the same time meeting the manufacturing requirements established by FDA for antibody supplementation in immunocompromised subjects. Areas covered: This review covers the manufacture and development of both RI-001 and RI-002, including the selection of plasma donors for IG preparation with high-titers of anti-RSV antibody, in vitro, and preclinical data in the cotton rat model S. hispidus, and clinical trials including Phase II and compassionate use studies of RI-001 and a multi-center, pivotal Phase III study of RI-002 in PIDD patients. Expert commentary: The data demonstrate that RI-002 is efficacious in the prevention and treatment of RSV in preclinical normal and immune suppressed animal models and is safe and efficacious in the treatment of patients with various forms of primary immunodeficiency disease (PIDD). This product offers potential advantages over other available IG’s for prophylaxis in immunocompromised patients requiring polyclonal immunoglobulin supplementation because of its unique antibody composition. In addition to its enhanced neutralizing anti-RSV activity and its polyclonal IG composition, there is preclinical data to support the use of RI-002 for humoral protection against other respiratory pathogens.
has issue date	2017-10-16(xsd:dateTime)
bibo:doi	10.1080/1744666x.2017.1389647
bibo:pmid	29035131
has license	no-cc
sha1sum (hex)	a701121045e7b0b260125caf9f75e2e5178f74e5
schema:url	https://doi.org/10.1080/1744666x.2017.1389647
resource representing a document's title	RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations
has PubMed Central identifier	PMC7103707
has PubMed identifier	29035131
schema:publication	Expert Rev Clin Immunol
resource representing a document's body	covid:a701121045e7b0b260125caf9f75e2e5178f74e5#body_text
is schema:about of	named entity 'efficacious' named entity 'Novel' named entity 'Phase II' named entity 'This' named entity 'data' named entity 'viruses' named entity 'CENTER' named entity 'INCLUDING' named entity 'PREPARATION' named entity 'DEVELOPMENT' named entity 'SELECTION' named entity 'ENHANCED' named entity 'IMMUNE GLOBULIN' named entity 'POTENTIAL' named entity 'MANUFACTURE' named entity 'IMMUNOCOMPROMISED' named entity 'VARIOUS' named entity 'FDA' named entity 'IMMUNE' named entity 'SUPPLEMENTATION' named entity 'DONORS' named entity 'SUPPRESSED' named entity 'ITS' named entity 'CLINICAL TRIALS' named entity 'PHASE II' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'RESPIRATORY VIRUSES' named entity 'RSV' named entity 'CONTAINING' named entity 'PRIMARY IMMUNODEFICIENCY DISEASE' named entity 'USE' named entity 'POPULATIONS' named entity 'TITER' named entity 'NEUTRALIZING ANTIBODY' named entity 'PROTECTION' named entity 'PRODUCTS' named entity 'UNIQUE' named entity 'FORMS' named entity 'MEDIATED' named entity 'PRIMARY IMMUNODEFICIENCY DISEASE' named entity 'TO SUPPORT' named entity 'NORMAL' named entity 'HIGH' named entity 'DATA' named entity 'PIDD' named entity 'PRODUCT' named entity 'ANIMAL MODELS ' named entity 'REVIEW' named entity 'MANUFACTURING' named entity 'IMMUNOGLOBULIN' named entity 'PROPHYLAXIS' named entity 'SAFE' named entity 'PLASMA' named entity 'PHASE III STUDY' named entity 'ESTABLISHED' named entity 'TREATMENT' named entity 'ADDITION' named entity '27S' named entity 'INTRAVENOUS IMMUNOGLOBULIN' named entity 'AREAS' named entity 'IMMUNE' named entity 'IN VITRO' named entity 'IMMUNOCOMPROMISED PATIENTS' named entity 'REQUIREMENTS' named entity 'COMMENTARY' named entity 'COMPOSITION' named entity 'USE STUDIES' named entity 'AVAILABLE' named entity 'PATIENTS' named entity 'ANTIBODY' named entity 'TIME' named entity 'MULTI' named entity 'HAVE' named entity 'ACTIVITY' named entity 'PREVENTION' named entity 'RAT MODEL' named entity 'HIGH' named entity 'COVERED' named entity 'RI-001'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software